Trial Profile
A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms TCHL-Phase-II
- 01 Jun 2021 Results performing tumour-associated lymphocytes analysis and T-cell analysis by immunohistochemistry on the pretreatment and on-treatment samples from NCT01485926, published in the Breast Cancer Research and Treatment
- 29 Oct 2020 Results published in the Clinical Cancer Research
- 24 Jun 2020 Results assessing effects of neo-adjuvant chemotherapy on the phenotype and cytotoxic capacity of peripheral blood mononuclear cells breast cancer patients presented at the 111th Annual Meeting of the American Association for Cancer Research - II